Login / Signup

Perspective on the Structural Basis for Human Aldo-Keto Reductase 1B10 Inhibition.

Francesc Xavier RuizXavier ParésJaume Farrés
Published in: Metabolites (2021)
Human aldo-keto reductase 1B10 (AKR1B10) is overexpressed in many cancer types and is involved in chemoresistance. This makes AKR1B10 to be an interesting drug target and thus many enzyme inhibitors have been investigated. High-resolution crystallographic structures of AKR1B10 with various reversible inhibitors were deeply analyzed and compared to those of analogous complexes with aldose reductase (AR). In both enzymes, the active site included an anion-binding pocket and, in some cases, inhibitor binding caused the opening of a transient specificity pocket. Different structural conformers were revealed upon inhibitor binding, emphasizing the importance of the highly variable loops, which participate in the transient opening of additional binding subpockets. Two key differences between AKR1B10 and AR were observed regarding the role of external loops in inhibitor binding. The first corresponded to the alternative conformation of Trp112 (Trp111 in AR). The second difference dealt with loop A mobility, which defined a larger and more loosely packed subpocket in AKR1B10. From this analysis, the general features that a selective AKR1B10 inhibitor should comply with are the following: an anchoring moiety to the anion-binding pocket, keeping Trp112 in its native conformation (AKR1B10-like), and not opening the specificity pocket in AR.
Keyphrases
  • high resolution
  • structural basis
  • endothelial cells
  • dna binding
  • binding protein
  • ionic liquid
  • squamous cell carcinoma
  • mass spectrometry
  • brain injury
  • papillary thyroid
  • young adults
  • high speed
  • childhood cancer